alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



EXHIBIT 31.2 CERTIFICATION PURSUANT TO
EXCHANGE ACT RULE 13a-14 I, David H. Thompson, Chief Financial Officer, certify that:  (1)
    
    I have reviewed this Form 10-QSB of International Absorbents Inc.;(2)
    
    Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;(3)
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the small
business issuer as of, and for, the periods presented in this report;(4)
    
    The small business issuers other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small
business issuer and have:  (a)
    
    Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the small business
issuer, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which
this report is being prepared;(b)
    
    Evaluated the effectiveness of the small business issuers
disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on
such evaluation; and(c)
    
    Disclosed in this report any change in the small business
issuers internal control over financial reporting that occurred during
the small business issuers most recent fiscal quarter (the small
business issuers fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially
affect, the small business issuers internal control over financial
reporting; and  (5)
    
    The small business issuers other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over
financial reporting, to the small business issuers auditors and the audit
committee of the small business issuers board of directors (or persons
performing the equivalent functions):  (a)
    
    All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the small business issuers
ability to record, process, summarize and report financial information;
and(b)
    
    Any fraud, whether or not material, that involves management or
other employees who have a significant role in the small business
issuers internal control over financial reporting. Date: December 8, 2004 /s/ DAVID H. THOMPSON  
 27
#### § 558.340 Maduramicin.

(a) *Specifications.* Type A medicated articles containing 4.54 grams maduramicin per pound.

(b) *Sponsor. See* No. 054771 in § 510.600(c) of this chapter.

(c) *Tolerances. See* § 556.375 of this chapter.

(d) *Conditions of use in chickens* —

| Amount in grams/ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- |
| (1) 4.54 to 5.45 | Broiler chickens: For prevention of coccidiosis caused by *Eimeria acervulina, E. tenella, E. brunetti, E. maxima, E. necatrix,* and *E. mivati* | Feed continuously as sole ration. For broiler chickens only. Do not feed to laying hens. Withdraw 5 days before slaughter | 054771 |
| (2) [Reserved] | | | |

[85 FR 45310, July 28, 2020]
§ 520.522 Cyclosporine. ( a ) *Specifications.* ( 1 ) Each cyclosporine capsule, USP (MODIFIED) contains 10, 25, 50, or 100 milligrams (mg) cyclosporine.
( 2 ) Each milliliter of cyclosporine oral solution, USP (MODIFIED) contains 100 mg cyclosporine.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter. ( 1 ) No. 058198 for use of products described in paragraph (a) as in paragraph (d) of this section.
( 2 ) No. 017033 for use of product described in paragraph (a)(1) as in paragraph (d)(1) of this section.
( 3 ) No. 051311 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(1) of this section.
( 4 ) No. 086097 for use of product described in paragraph (a)(2) as in paragraph (d) of this section.
( c ) [Reserved]
( d ) *Conditions of use* — ( 1 ) *Dogs.* Use capsules described in paragraph (a)(1) of this section as follow: ( i ) *Amount.* Administer 5 mg per kilogram (mg/kg) of body weight given orally as a single daily dose for 30 days. Following this initial daily treatment period, the dosage may be tapered by decreasing the frequency of administration to every other day or two times a week, until a minimum frequency is reached which will maintain the desired therapeutic effect.
( ii ) *Indications for use.* For the control of atopic dermatitis in dogs weighing at least 4 pounds.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cats.* Use the solution described in paragraph (a)(2) of this section as follow: ( i ) *Amount.* Administer 7 mg/kg of body weight orally as a single daily dose for a minimum of 4 to 6 weeks or until resolution of clinical signs. Following this initial daily treatment period, the dosage may be tapered by decreasing the frequency of administration to every other day or twice weekly to maintain the desired therapeutic effect.
( ii ) *Indications for use.* For the control of feline allergic dermatitis as manifested by excoriations (including facial and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and at least 3 lbs (1.4 kg) in body weight.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[68 FR 54804, Sept. 19, 2003, as amended at 76 FR 78815, Dec. 20, 2011; 84 FR 12493, Apr. 2, 2019; 86 FR 17063, Apr. 1, 2021; 88 FR 16547, Mar. 20, 2023; 88 FR 27698, May 3, 2023]
EXHIBIT 32.1





CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER





Pursuant to Section 906 of the Sarbanes Oxley Act of 2002 (18 U.S.C. 1350) and


Rules 13a-14(b) of the Securities Exchange Act of 1934





I, Daniel A. Ninivaggi, President of Icahn Enterprises G.P. Inc., the general partner of Icahn Enterprises L.P., certify that, to the best of my knowledge, based upon a review of the Icahn Enterprises L.P. quarterly report on Form 10-Q for the period ended March 31, 2011 of the registrant:





(1) The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and





(2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the registrant.





/s/  Daniel A. NinivaggiDaniel A. NinivaggiPresident of Icahn Enterprises G.P. Inc., the general partner of Icahn Enterprises L.P.





Date: May 4, 2011
# C_2014235EN.01000501.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/5 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/5

---

Request for a preliminary ruling from the Tribunalul Sibiu (Romania) lodged on 22 April 2014 — Silvia Georgiana Câmpean v Administrația Finanțelor Publice a Municipiului Mediaș, Administrația Fondului pentru Mediu București

(Case C-200/14)

2014/C 235/06

Language of the case: Romanian

Referring court

Referring court

Tribunalul Sibiu

Parties to the main proceedings

Parties to the main proceedings

Applicant: Silvia Georgiana Câmpean

Applicant:

Defendants: Administrația Finanțelor Publice a Municipiului Mediaș, Administrația Fondului pentru Mediu București

Defendants:

Question referred

Question referred

On a proper construction of Article 6 of the Treaty on European Union, Articles 17, 20, 21(1) and 47 of the Charter of Fundamental Rights of the European Union, the principle laid down in the case-law of the Court of Justice that taxes prohibited by EU law must be refunded, Recommendation Rec (2003)16 of the Committee of Ministers of the Council of Europe and Resolution 1787 (2011) of the Parliamentary Assembly of the Council of Europe, is it possible that a provision such as Article XV of Emergency Government Order No 8/2014 is thereby precluded?

---
EXHIBIT
32.2


CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,


AS
ADOPTED PURSUANT TO SECTION 906 OF THE


SARBANES-OXLEY
ACT OF 2002





In 
connection  with the quarterly report of Avitar,  Inc. (the 
"Company") on Form10-QSB/A for the period ending December 31, 2007 as filed with
the Securities and Exchange  Commission on the date hereof (the 
"Report"),  I, Jay C. Leatherman,  Jr., Chief Financial 
Officer of the Company  certify,  pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley Act of
2002, to my knowledge, that:





(1) The Report fully  complies  with the  requirements  of
Section 13(a) or15(d) of the Securities Exchange Act of 1934; and





(2)  The  information  contained  in the  Report 
fairly  presents,  in all material  respects,  the 
financial  condition  and results of operations of the
Company.





Date:
February 14, 2008





/s/ Jay C. Leatherman, Jr.


-------------------------


Jay
C. Leatherman, Jr.


Chief
Financial Officer (Principal Financial


and
Accounting Officer), Secretary
# L_2018251EN.01002401.xml

| 5.10.2018 | EN | Official Journal of the European Union | L 251/24 |
| --- | --- | --- | --- |

5.10.2018

EN

Official Journal of the European Union

L 251/24

---

COMMISSION IMPLEMENTING REGULATION (EU) 2018/1484

of 4 October 2018

on the minimum selling price for skimmed milk powder for the 25th partial invitation to tender within the tendering procedure opened by Implementing Regulation (EU) 2016/2080

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 1308/2013 of the European Parliament and of the Council of 17 December 2013 establishing a common organisation of the markets in agricultural products and repealing Council Regulations (EEC) No 922/72, (EEC) No 234/79, (EC) No 1037/2001 and (EC) No 1234/2007 (1),

Having regard to Commission Implementing Regulation (EU) 2016/1240 of 18 May 2016 laying down rules for the application of Regulation (EU) No 1308/2013 of the European Parliament and of the Council with regard to public intervention and aid for private storage (2), and in particular Article 32 thereof,

Whereas:

| (1) | Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure. |
| --- | --- |

(1)

Commission Implementing Regulation (EU) 2016/2080 (3) has opened the sale of skimmed milk powder by a tendering procedure.

| (2) | In the light of the tenders received for the 25th partial invitation to tender, a minimum selling price should be fixed. |
| --- | --- |

(2)

In the light of the tenders received for the 25th partial invitation to tender, a minimum selling price should be fixed.

| (3) | The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets, |
| --- | --- |

(3)

The measures provided for in this Regulation are in accordance with the opinion of the Committee for the Common Organisation of the Agricultural Markets,

HAS ADOPTED THIS REGULATION:

Article 1

For the 25th partial invitation to tender for the selling of skimmed milk powder within the tendering procedure opened by Implementing Regulation (EU) 2016/2080, in respect of which the period during which tenders were to be submitted ended on 2 October 2018, the minimum selling price shall be 123 EUR/100 kg.

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 4 October 2018.

For the Commission,

On behalf of the President,

Jerzy PLEWA

Director-General

Directorate-General for Agriculture and Rural Development

---

(1)  
  OJ L 347, 20.12.2013, p. 671.

1

(2)  
  OJ L 206, 30.7.2016, p. 71.

2

(3)  Commission Implementing Regulation (EU) 2016/2080 of 25 November 2016 opening the sale of skimmed milk powder by a tendering procedure (OJ L 321, 29.11.2016, p. 45).

3

---
### A study of coastal ground water, with special reference to Connecticut

By: John Stafford Brown

                            https://doi.org/10.3133/wsp537

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
§ 209.11 Dispensing and distributing the side effects statement. ( a ) Each authorized dispenser or pharmacy must distribute the side effects statement with each prescription drug product approved under section 505 of the act and dispensed. The side effects statement must be distributed with new and refill prescriptions.
( b ) An authorized dispenser or pharmacy must choose one or more of the following options to distribute the side effects statement: ( 1 ) Distribute the side effects statement on a sticker attached to the unit package, vial, or container of the drug product;
( 2 ) Distribute the side effects statement on a preprinted pharmacy prescription vial cap;
( 3 ) Distribute the side effects statement on a separate sheet of paper;
( 4 ) Distribute the side effects statement in consumer medication information; or
( 5 ) Distribute the appropriate FDA-approved Medication Guide that contains the side effects statement.
§ 529.56 Amikacin. ( a ) *Specifications.* Each milliliter (mL) of solution contains 250 milligrams of amikacin as amikacin sulfate.
( b ) *Sponsors.* See Nos. 054771 and 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 2 grams (8 mL) diluted with 200 mL of sterile physiological saline by intrauterine infusion daily for 3 consecutive days.
( 2 ) *Indications for use.* For treating genital tract infections (endometritis, metritis, and pyometra) in mares caused by susceptible organisms including *Escherichia coli, Pseudomonas* spp., and *Klebsiella* spp.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[76 FR 17339, Mar. 29, 2011, as amended at 78 FR 17597, Mar. 22, 2013; 79 FR 10973, Feb. 27, 2014; 86 FR 14821, Mar. 19, 2021]
§ 1305.12 Procedure for executing DEA Forms 222. ( a ) A purchaser must prepare and execute a DEA Form 222 by use of a typewriter, computer printer, pen, or indelible pencil.
( b ) Only one item may be entered on each numbered line. An item must consist of one or more commercial or bulk containers of the same finished or bulk form and quantity of the same substance. The number of lines completed must be noted on that form at the bottom of the form, in the space provided. DEA Forms 222 for carfentanil, etorphine hydrochloride, and diprenorphine must contain only these substances.
( c ) The name and address of the supplier from whom the controlled substances are being ordered must be entered on the form. Only one supplier may be listed on any form. The supplier's DEA registration number may be entered by the purchaser or the supplier.
( d ) Each DEA Form 222 must be signed and dated by a person authorized to sign an application for registration or a person granted power of attorney to sign a Form 222 under § 1305.05. The name of the purchaser, if different from the individual signing the DEA Form 222, must also be inserted in the signature space.
( e ) Unexecuted DEA Forms 222 may be kept and may be executed at a location other than the registered location printed on the form, provided that all unexecuted forms are delivered promptly to the registered location upon an inspection of the location by any officer authorized to make inspections, or to enforce, any Federal, State, or local law regarding controlled substances.
[70 FR 16911, Apr. 1, 2005, as amended at 84 FR 51374, Sept. 30, 2019; 86 FR 38232, July 20, 2021]
Exhibit 32



Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)



The undersigned, as the Chairman, President and Chief Executive Officer, and Interim Chief Financial Officer, Vice President
and Corporate Controller of Exide Technologies, each certify that the Quarterly Report on Form 10-Q for the period ended December 31, 2003, which accompanies this certification fully complies with the requirements of Section 13(a) or 15(d), as
applicable, of the Securities Exchange Act of 1934 and the information contained in the periodic report fairly presents, in all material respects, the financial condition and results of operations of Exide Technologies at the dates and for the
periods indicated. The foregoing certification is made pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.§1350) and no purchaser or seller of securities or any other person shall be entitled to rely upon the
foregoing certification for any other purpose. A signed original of this written statement required by Section 906 has been provided to Exide Technologies and will be retained by Exide Technologies and furnished to the Securities and Exchange
Commission or its staff upon request.



The undersigned
expressly disclaims any obligation to update the foregoing certification except as required by law.



Date: Febuary 17, 2004



/s/    CRAIG H. MUHLHAUSERCraig H. Muhlhauser Chairman, President and Chief Executive Officer


/s/    IAN J. HARVIEIan J. HarvieInterim Chief Financial Officer, Vice President and Corporate Controller
§ 520.1158 Iodochlorhydroxyquin. ( a ) *Specifications.* Each bolus contains 10 grams of iodochlorhydroxyquin.
( b ) *Sponsor.* See No. 054771 in § 510.600 (c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* 1 bolus (10 grams) daily for a 1,000-pound horse.
( 2 ) *Indications for use.* For treatment of equine diarrhea.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[48 FR 8054, Feb. 25, 1983, as amended at 50 FR 41489, Oct. 11, 1985; 78 FR 28822, May 20, 2014]
<PAGE>

                                                                      Exhibit 32

Pursuant to (S) 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. (S) 1350)

     The undersigned, as the Chairman, President and Chief Executive Officer,
and Executive Vice President and Chief Financial Officer of Exide Technologies,
each certify that the Quarterly Report on Form 10-Q for the period ended June
30, 2003, which accompanies this certification fully complies with the
requirements of Section 13(a) or 15(d), as applicable, of the Securities
Exchange Act of 1934 and the information contained in the periodic report fairly
presents, in all material respects, the financial condition and results of
operations of Exide Technologies at the dates and for the periods indicated. The
foregoing certification is made pursuant to (S) 906 of the Sarbanes-Oxley Act of
2002 (18 U.S.C. (S) 1350) and no purchaser or seller of securities or any other
person shall be entitled to rely upon the foregoing certification for any other
purpose. A signed original of this written statement required by Section 906 has
been provided to Exide Technologies and will be retained by Exide Technologies
and furnished to the Securities and Exchange Commission or its staff upon
request.

The undersigned expressly disclaims any obligation to update the foregoing
certification except as required by law.

Date: August 14, 2003


                           /s/ Craig H. Muhlhauser
                           ----------------------------------------
                           Craig H. Muhlhauser
                           Chairman, President and Chief Executive Officer


                           /s/ Biagio N. Vignolo, Jr.
                           ----------------------------------------
                           Biagio N. Vignolo, Jr.
                           Executive Vice President and Chief Financial Officer
§ 1107.40 Communications between FDA and applicants. ( a ) *General principles.* During the course of reviewing an SE Report, FDA may communicate with applicants about relevant matters, including scientific, medical, and procedural issues that arise during the review process. These communications may take the form of telephone conversations, letters, or emails, and will be documented in the SE Report in accordance with § 10.65 of this chapter.
( b ) *Meeting.* Meetings between FDA and applicants may be held to discuss scientific and other issues. Requests for meetings will be directed to the Office of Science, Center for Tobacco Products, and FDA will make every attempt to grant requests for meetings that involve important issues.
( c ) *Acceptance of an SE Report for review.* After receiving an SE Report under § 1107.18, FDA will either refuse to accept the SE Report for review or issue an acceptance for review letter.
( d ) *Notification of deficiencies in an SE Report submitted under § 1107.18 .* FDA will make reasonable efforts to communicate to applicants the procedural, administrative, or scientific deficiencies found in an SE Report and any additional information and data needed for the Agency's review. The applicant must also provide additional comparison information under § 1107.19 if requested by FDA.
( e ) *Withdrawal of SE Report.* An SE Report will be considered withdrawn when FDA issues a notice stating that the SE Report has been withdrawn.
FILED

October 9, 1998

Cecil W. Crowson

Appellate Court Clerk

IN THE COURT OF APPEALS OF TENNESSEE

AT NASHVILLE

MATHIVATHANI MOHAN, )

)

Plaintiff/Appellee, ) Appeal No.

) 01-A-01-9708-CV-00415

)

VS. ) Davidson Circuit

) No. 96D-373

)

RATHNASABAPATHY MOHAN, )

)

Defendant/Appellant. )

DISSENTING OPINION

I respectfully dissent from the majority opinion because I do not think the

trial judge abused her discretion in denying the appellant’s motion for a new trial. The

appellant’s motion does not set out what proof he would offer at a new trial and how

that might change the result below. Therefore, I think the trial judge justifiably

overruled the motion.

_________________________________

BEN H. CANTRELL, JUDGE